Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197

PURPOSE: The combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant regimen. Doxorubicin and docetaxel (AT) is one of the most active cytotoxic regimens for metastatic breast cancer. The purpose of this trial was to determine whether adjuvant AT improved disease-free survival co...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Goldstein, Lori J., O'Neill, Anne, Sparano, Joseph A., Perez, Edith A., Shulman, Lawrence N., Martino, Silvana, Davidson, Nancy E.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2008
Materias:
Breast Cancer
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2654376/
https://ncbi.nlm.nih.gov/pubmed/18678836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.16.7841
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares